Eko Health, a leader in AI-driven cardiac and pulmonary disease detection, has received a Category III CPT code from the AMA for its SENSORA™ platform, marking a significant step toward coverage and reimbursement for early heart disease detection. Effective July 1, 2025, this designation will help expand access to SENSORA™, equipping clinicians across the U.S. with powerful AI tools to identify heart issues in primary care settings.
SENSORA™, which integrates with the Eko CORE 500™ digital stethoscope, uses FDA-cleared algorithms to detect cardiac conditions such as structural heart murmurs, low ejection fraction, and AFib, aiding early diagnosis and proactive management. In a clinical study published in Circulation, SENSORA’s algorithms doubled the sensitivity for detecting structural heart disease, while a separate Lancet Digital Health study demonstrated its accuracy in identifying low ejection fraction among 1,000+ patients, leading to its adoption in over 100 UK clinics.
Given heart disease’s position as the leading cause of death in the U.S., early detection is essential for better patient outcomes. By empowering primary care providers with validated AI tools, SENSORA™ facilitates timely intervention, bridging gaps in preventive care and helping manage advanced disease progression.
Connor Landgraf, CEO of Eko Health, highlighted the impact of the CPT code, stating, “The AMA’s new Category III CPT code for our AI algorithms is a major step toward increasing access to early heart disease detection. This milestone will allow clinicians to use powerful, validated tools to improve patient outcomes, particularly in underserved communities.”
Click here to read the original news story.